The Latest Breathing Disorders Treatment Industry Statistics Explained
“Chronic Obstructive Pulmonary Disease (COPD) treatments market size was valued at $14,548 million in 2020 and is anticipated to reach $26,527 million by 2030.”
This statistic indicates the current and projected market size for Chronic Obstructive Pulmonary Disease (COPD) treatments, which was valued at $14,548 million in 2020 and is expected to increase to $26,527 million by the year 2030. This growth rate suggests a significant market expansion over the next decade. Factors contributing to this growth may include an increasing prevalence of COPD, advancements in treatment options, growing awareness and diagnosis rates, and evolving healthcare infrastructure. This statistic serves as an important indicator of the market demand and investment opportunities within the COPD treatment sector, highlighting the potential for continued growth and innovation in managing this chronic respiratory condition.
“The asthma market is expected to grow at a CAGR of 2.2% to nearly $22.6 billion by 2023.”
This statistic indicates that the asthma market is forecasted to experience a Compound Annual Growth Rate (CAGR) of 2.2% between the present time and the year 2023, reaching a market value of nearly $22.6 billion. This growth rate suggests a steady increase in the market size over the specified period, driven by factors such as rising prevalence of asthma, advancements in treatment options, and increasing healthcare expenditure on respiratory diseases. The projected growth indicates the potential for continued market expansion and investment opportunities within the asthma market in the foreseeable future.
“Globally, 1.3 billion people suffer from chronic respiratory conditions.”
The statistic “Globally, 1.3 billion people suffer from chronic respiratory conditions” indicates that there are approximately 1.3 billion individuals worldwide who are affected by long-term respiratory issues. Chronic respiratory conditions encompass a range of ailments, such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis, among others. These conditions can have significant impacts on an individual’s quality of life, leading to symptoms like coughing, wheezing, and shortness of breath. The statistic underscores the significant burden that respiratory diseases pose on global public health, highlighting the importance of preventative measures, early detection, and effective management strategies to alleviate the impact of these conditions on affected individuals.
“North America respiratory drugs market is estimated to grow by 1.7% annually, reaching $58.02 billion by 2025.”
The statistic indicates the projected growth rate of the North America respiratory drugs market, estimating an annual growth rate of 1.7%. This growth is expected to lead to a market size of $58.02 billion by the year 2025. The statistic suggests a gradual but steady expansion of the market for respiratory drugs in North America over the specified time frame. Factors such as increasing respiratory health concerns, advancements in drug development, and a growing elderly population may contribute to this anticipated growth in the market. Additionally, increased awareness and investment in respiratory health care could also play a role in driving the growth of the market for respiratory drugs in North America.
“The sales share of the inhalation route in the respiratory diseases treatment market was nearly 55% in 2019.”
This statistic indicates that among all the routes of administration utilized for treating respiratory diseases in 2019, the inhalation route accounted for approximately 55% of the total sales share. This implies that a majority of the revenue generated within the respiratory diseases treatment market was attributed to medications or therapies that are administered through inhalation. The popularity and success of inhalation therapies could be influenced by factors such as the effectiveness of delivering medication directly to the lungs, ease of administration for patients, and the ability to target specific areas within the respiratory system. This statistic highlights the significant role that inhalation-based treatments play in the management and treatment of respiratory conditions.
“Europe respiratory care devices market is expected to reach USD 9.69 Billion by 2027.”
The statistic “Europe respiratory care devices market is expected to reach USD 9.69 Billion by 2027” indicates the projected total value of the market for respiratory care devices in Europe by the year 2027. This figure represents the estimated amount of revenue that is expected to be generated from the sales of respiratory care devices in the European region. The market size is a significant indicator of the growth and demand for respiratory care devices in Europe, reflecting the increasing focus on respiratory health and the need for medical devices to address respiratory conditions. The forecasted value of USD 9.69 Billion suggests a growing market opportunity for manufacturers and suppliers of respiratory care devices in Europe over the coming years.
“Global artificial respiratory market size was valued at USD 1.42 billion in 2019 and is expected to register a CAGR of 10.0% over the forecast period.”
This statistic states that the global artificial respiratory market was worth USD 1.42 billion in 2019 and is projected to experience a Compound Annual Growth Rate (CAGR) of 10.0% over the forecast period. The CAGR indicates the average annual growth rate of the market size from 2019 to the end of the forecast period. This information suggests that the artificial respiratory market is anticipated to expand steadily at a consistent rate of 10.0% per year, potentially reaching a higher market value in the coming years. This trend reflects a positive outlook on the demand for artificial respiratory devices and technologies in the healthcare industry, likely driven by factors such as increasing prevalence of respiratory diseases and advancements in medical technology.
“US dominated the North America respiratory devices market at $6.5 billion in 2019.”
The statistic “US dominated the North America respiratory devices market at $6.5 billion in 2019” indicates that the United States held a significant market share in the respiratory devices industry in North America during that year, with a total market value of $6.5 billion. This suggests that the US had a strong presence in providing respiratory devices such as ventilators, CPAP machines, nebulizers, and oxygen therapy equipment within the region, outperforming competitors in terms of market size and revenue generation. The statistic highlights the importance of the US market within North America for respiratory devices and signifies the country’s leading position in meeting the healthcare needs related to respiratory conditions.
“Cystic fibrosis therapeutics market is valued at $3.56 billion in 2020 and expected to reach $7.99 billion by 2025.”
The statistic highlights the current and projected market value of cystic fibrosis therapeutics, which is estimated at $3.56 billion in 2020 and expected to grow to $7.99 billion by 2025. This indicates a significant anticipated increase in market size over the next five years, reflecting the growing demand and advancements in treatments for cystic fibrosis. The projected growth suggests a positive outlook for the cystic fibrosis therapeutic market, with potential opportunities for investment, research, and development in this sector.
“Asia pacific respiratory disorders inhalers market size was valued at $3.02 billion in 2019.”
The statistic “Asia Pacific respiratory disorders inhalers market size was valued at $3.02 billion in 2019” indicates the total monetary worth of the market for inhalers used in the treatment of respiratory disorders in the Asia Pacific region for the year 2019. This value reflects the revenue generated by sales of various types of inhalers, such as metered dose inhalers (MDIs) and dry powder inhalers (DPIs), across countries in the Asia Pacific region. The market size represents the demand for respiratory inhalers and indicates the significant presence of respiratory disorders in the region, driving the need for pharmaceutical companies to produce and market such products to meet the healthcare needs of the population.
“Respiratory monitoring devices market expected to grow at a CAGR of 8.5% to reach $2.24 billion by 2025.”
The statistic indicates that the respiratory monitoring devices market is projected to experience a compound annual growth rate (CAGR) of 8.5% over the forecast period, leading to a total market value of $2.24 billion by the year 2025. This growth rate suggests a steady and substantial increase in the demand for respiratory monitoring devices, likely driven by factors such as technological advancements, increasing prevalence of respiratory diseases, and growing awareness about the importance of respiratory health monitoring. The $2.24 billion market value by 2025 reflects the estimated size and value of the market at that future point in time, highlighting the significant market potential for respiratory monitoring devices in the coming years.
“In 2020, the top 3 players in the global Asthma & COPD treatments market, GlaxoSmithKline ($GSK), AstraZeneca ($AZN) and Boehringer Ingelheim, had a cumulative market share of approximately 70%.”
The statistic indicates that in 2020, the three leading players in the global Asthma and Chronic Obstructive Pulmonary Disease (COPD) treatments market, GlaxoSmithKline (GSK), AstraZeneca (AZN), and Boehringer Ingelheim, collectively held a significant market share of around 70%. This suggests that these companies were the dominant players in the industry and had a substantial influence on the overall market dynamics and competition. The high cumulative market share of these top three companies highlights their strong positions within the Asthma and COPD treatments market, potentially signaling the competitive landscape and market concentration within the industry.
“It’s projected that by 2026, the sleep apnea devices industry is expected to surpass $9 billion.”
This statistic indicates that the sleep apnea devices industry is forecasted to experience significant growth by the year 2026, with expected revenues exceeding $9 billion. This projection suggests that sleep apnea devices are becoming increasingly prevalent and in-demand, likely as a result of rising awareness and diagnosis of sleep apnea conditions. Factors such as an aging population, technological advancements in device efficacy and comfort, and a greater emphasis on sleep health may contribute to the industry’s growth. The expanding market for sleep apnea devices underscores the importance of addressing and treating sleep-related disorders, highlighting opportunities for both manufacturers and healthcare providers in this sector.
“By 2027, the global respiratory drug delivery market is projected to reach USD 52.37 billion, from an estimated USD 41.20 billion in 2021, growing at a CAGR of 4.19%.”
This statistic indicates the projected growth of the global respiratory drug delivery market from 2021 to 2027. The market is expected to increase from an estimated value of USD 41.20 billion in 2021 to USD 52.37 billion by 2027, representing a compound annual growth rate (CAGR) of 4.19%. This growth rate suggests a steady and consistent increase in market size over the period, driven by factors such as increasing prevalence of respiratory diseases, advancements in drug delivery technologies, and rising healthcare expenditure globally. The statistic highlights the significant opportunities and potential for growth in the respiratory drug delivery market in the coming years.
“The China respiratory care devices market is expected to grow at a CAGR of 8.4% from 2019 to 2027 to reach $1.48 billion by 2027.”
This statistic indicates that the China respiratory care devices market is projected to experience a Compound Annual Growth Rate (CAGR) of 8.4% between 2019 and 2027. This means that the market is expected to steadily increase at an average annual rate of 8.4% over this period. By the end of 2027, the market is forecasted to reach a total value of $1.48 billion. This growth rate suggests a positive trend in the demand for respiratory care devices in China, likely driven by factors such as an aging population, increasing prevalence of respiratory diseases, and advancements in healthcare technology.
“In the US, COPD is estimated to affect 16 million people, and COPD and lung cancer combined accounted for 9.3% of total deaths in 2015.”
The statistic provided highlights the significant impact of Chronic Obstructive Pulmonary Disease (COPD) on public health in the United States. With an estimated 16 million people affected by COPD, it underlines the widespread nature of the disease and the burden it places on individuals and healthcare systems. Furthermore, the mention that COPD and lung cancer combined accounted for 9.3% of total deaths in 2015 illustrates the lethal consequences of these respiratory conditions. This statistic underscores the urgent need for effective prevention strategies, early detection, and improved management of COPD to reduce the mortality and morbidity associated with these diseases.
References
0. – https://www.www.marketdataforecast.com
1. – https://www.www.futuremarketinsights.com
2. – https://www.www.who.int
3. – https://www.www.alliedmarketresearch.com
4. – https://www.www.pharmaceutical-technology.com
5. – https://www.www.gminsights.com
6. – https://www.www.grandviewresearch.com
7. – https://www.www.researchandmarkets.com
8. – https://www.www.marketresearchfuture.com
9. – https://www.www.thefastmode.com
10. – https://www.www.mordorintelligence.com
11. – https://www.www.databridgemarketresearch.com
12. – https://www.www.marketsandmarkets.com
